Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ENTX

Entera Bio

ENTX Rare disease Lead: Phase 2 1 Biotech Distilled article ↓ 35 filings & releases ↓ Cash $266M (Sep 30, 2026) ↓ 1 verdict ↓ 5 timing quotes ↓
GI/HepatologyMetabolic Peptide

Market cap $547M 174.1M shares (10-Q, Nov 2, 2026) × $3.14 close Nov 6, 2026

Most recent annual filing: 2026-03-27

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. EB618 IND filing2026EB618 IND filing, 2026, notable
  2. EB613 Ph3 startLate 2026EB613 Ph3 start, Late 2026, routine
  3. EB612 IND filing1H 2027EB612 IND filing, 1H 2027, notable
  4. EB613 / pipeline enrollment done2027EB613 / pipeline enrollment done, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Technology platforms

N-Tab

Proprietary oral peptide and protein delivery technology platform enabling oral bioavailability of peptides; underpins Entera's pipeline of first-in-class oral peptide programs including PTH(1-34), acylated PTH(1-34), oxyntomodulin (GLP1/glucagon), and GLP-2 candidates across osteoporosis, hypoparathyroidism, obesity, and rare malabsorption conditions.

Capital (as filed)

Cash
$266M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$7.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$11.9M cash, runway 2030 per the deep dive of Jul 29, 2026 — the company's own words as read there, not the filed figure

Offering documents (2)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (1 call)

Every verdict Biotech Distilled has published on Entera Bio, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-07-30 Watch Entera Bio (ENTX) — Scientific Deep Dive for EB613 and the N-Tab® Oral Peptide Pipeline Despite a de-risked mechanism and strong balance sheet post-financing, the 21-patient efficacy signal, untested Phase 3 dose, primary endpoint outside FDA's qualified 24-month context of use, and 85% post-financing markup into a 26-month catalyst desert make this the wrong entry at the wrong price.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (5 quotes from 4 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (35)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 29, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

14 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)